



Our Pipeline

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.



Program	Approach	Research	Candidate Selection	IND-Enabling	Phase 1	Phase 2	Phase 3	Partner
<i>In Vivo</i>: CRISPR <u>is</u> the therapy								
NTLA-2001: Transthyretin Amyloidosis	Knockout	[Progress bar]						LEAD Intellia* REGENERON
NTLA-2002: Hereditary Angioedema	Knockout	[Progress bar]						Intellia
Hemophilia A and B	Insertion	[Progress bar]						LEAD REGENERON* Intellia
Research Programs	Knockout, Insertion, Consecutive Edits	[Progress bar]						Intellia
Research Programs	Various	[Progress bar]						Intellia REGENERON**
<i>Ex Vivo</i>: CRISPR <u>creates</u> the therapy								
OTQ923 / HIX763: Sickle Cell Disease	HSC	[Progress bar]			Phase 1/2			NOVARTIS Intellia***
NTLA-5001: Acute Myeloid Leukemia	WT1-TCR	[Progress bar]						Intellia
Solid Tumors	WT1-TCR	[Progress bar]						Intellia
Undisclosed Programs	Undisclosed	[Progress bar]						Intellia
Other Novartis Programs	CAR-T, HSC, OSC				UNDISCLOSED			NOVARTIS Intellia***



* Lead development and commercial party royalties

CAR-T: Chimeric Antigen Receptor T cells

** Rights to certain *in vivo* targets

HSC: Hematopoietic Stem Cells

*** Milestones &

OSC: Ocular Stem Cells

Updated October 19, 2020